You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

Article metrics

Article menu

Download PDFPDF

Cervical cancer
164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy
Free

 

Online download statistics by month:

Online download statistics by month: October 2021 to October 2024

AbstractFullPdf
Oct 202167015
Nov 202179023
Dec 20211701
Jan 20226108
Feb 20222508
Mar 202231011
Apr 2022503
May 202220017
Jun 20222907
Jul 20221501
Aug 20222506
Sep 20221805
Oct 20223409
Nov 20221904
Dec 20222505
Jan 20231906
Feb 20232801
Mar 20231403
Apr 20232005
May 2023603
Jun 20232007
Jul 20231302
Aug 2023203
Sep 20231904
Oct 20232405
Nov 20232803
Dec 20234200
Jan 20242002
Feb 20242406
Mar 2024802
Apr 20241705
May 20243004
Jun 20241604
Jul 20243306
Aug 20243405
Sep 20241402
Oct 2024200
Total9030201